Related Experiment Videos
[Clinical evaluation of T-1982 (cefbuperazone) in the pediatric infections]
Insights
Cefbuperazone (T-1982) demonstrated an 85.7% efficacy rate in treating bacterial infections in children. This parenteral antibiotic proved safe and effective for various pediatric infections, with minimal adverse reactions observed.
Area of Science:
- Pediatric Infectious Diseases
- Antibiotic Therapy
- Pharmacokinetics
Background:
- Bacterial infections pose a significant health risk in pediatric populations.
- Effective parenteral antibiotic options are crucial for treating severe pediatric infections.
- Cefbuperazone (T-1982) is a cephalosporin antibiotic with potential utility in pediatric care.
Purpose of the Study:
- To evaluate the efficacy and safety of cefbuperazone (T-1982) in treating bacterial infections in children.
- To determine the pharmacokinetic profile of cefbuperazone (T-1982) in pediatric patients.
- To identify specific pathogens susceptible to cefbuperazone (T-1982) treatment.
Main Methods:
- Prospective evaluation of 25 children with suspected bacterial infections.
- Intravenous administration of cefbuperazone (T-1982).
- Clinical assessment of treatment efficacy, pathogen identification, and adverse reactions; serum half-life determination.
Main Results:
- Cefbuperazone (T-1982) showed an 85.7% efficacy rate in 21 confirmed bacterial infections.
- Effective treatment observed in pneumonia, bronchopneumonia, acute bronchitis, and other infections.
- Pathogens including Haemophilus influenzae, Staphylococcus aureus, and Escherichia coli were targeted; 7 strains eradicated.
- Serum half-life was 1.2 hours; no severe adverse reactions reported.
Conclusions:
- Cefbuperazone (T-1982) is an effective and safe parenteral antibiotic for susceptible pediatric bacterial infections.
- The drug demonstrates a favorable safety profile and pharmacokinetic characteristics in children.
- Further investigation may be warranted for specific resistant infections, such as Salmonella.
Abstract:
T-1982 (cefbuperazone) was evaluated in 25 children with a suspicion of bacterial infections, of the 21 confirmed bacterial infections, 18 were shown to be effective (efficacy rate, 85.7%). The diagnosis included pneumonia (4), bronchopneumonia (3), acute bronchitis (4), acute pharyngitis (1), acute laryngitis (1), acute epiglottitis (1), acute enterocolitis (3), cervical lymphadenitis (1), acute pyelonephritis (1) and suspected septicemia (2). The etiologic pathogens recovered were Haemophilus influenzae (4), Staphylococcus aureus (2), Salmonella typhimurium (1), Salmonella subgenus (1), and enteropathogenic Escherichia coli (2). Among these strains, 7 strains were eradicated after treatment. A case of suspected septicemia and 2 cases of acute enterocolitis with Salmonella infection were not effectively treated with T-1982. The serum half-life of T-1982 was 1.2 hours after an intravenous bolus injection. No severe adverse reaction was encountered with the T-1982 therapy. The data suggest that T-1982 is an effective and safe parenteral antibiotic in the treatment of susceptible pediatric bacterial infections.